Bristol-myers Squibb Co.

Organisation

Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Headquarters

32500

Employees

Health Technology

Industry

Giovanni Caforio

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Price

Target

Bristol-myers Squibb Co. (BMY) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Bristol-myers Squibb Co. (BMY) share price will touch around $62.72 in next 12-months.

Currently 31 wall-street analysts regularly analyze the financials of Bristol-myers Squibb Co. on a frequent basis to provide recommendations along with target share price. 31 analysts offering 12-month price forecasts for Bristol-myers Squibb Co. (BMY) have a share price target of $62.72. This median of share price forecast represents a 7.18% upside from the latest price of $58.52 as on 30.03.26.

Bristol-myers Squibb Co. (BMY) Share Price Forecast

Home

US Stocks

Bristol-myers Squibb Co. (BMY)

Bristol-myers Squibb Co. Stock Forecast

Bristol-myers Squibb Co. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Bristol-myers Squibb Co. (BMY): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Bristol-myers Squibb Co.'s share price and its median forecast price. As on 30.03.26, the difference is -10.72%

Bristol-myers Squibb Co. Forecast and Target Price

Bristol-myers Squibb Co. (BMY) Share Price Forecast

Bristol-myers Squibb Co. (BMY) Price vs Consensus Price Target

Bristol-myers Squibb Co. (BMY) Share Price Forecast v/s Share Price Today

Bristol-myers Squibb Co. (BMY): Difference between Current Price & Median Forecasted Price

Bristol-myers Squibb Co. (BMY) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price